The Lott

Lotte Biologics is a South Korean contract development and manufacturing organization (CDMO) and a subsidiary of the Lotte Group. Established in 2022, the company entered the global market through the acquisition of a major manufacturing facility in East Syracuse, New York, from Bristol Myers Squibb. Lotte Biologics provides end-to-end services for the development and production of biologics, including monoclonal antibodies and antibody-drug conjugates (ADCs). The company is currently expanding its global footprint with plans to build large-scale manufacturing hubs in South Korea, specifically in Songdo, to meet the growing demand for biopharmaceutical production. Its business model focuses on high-quality manufacturing standards and strategic partnerships with global pharmaceutical companies.